<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="f4a673c4-d52c-4707-ac92-59373839ca6a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Cleocin<sup>Â®</sup>
      </content>
      <br/>
      <content styleCode="bold">clindamycin phosphate vaginal cream, USP</content>
   </title>
   <effectiveTime value="20250403"/>
   <setId root="f9be442d-0782-4b93-828f-9ebbf67dbced"/>
   <versionNumber value="22"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
            <name>Pharmacia &amp; Upjohn Company LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
                        <name>Pharmacia &amp; Upjohn Company LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-3448" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-3448" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-3448" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-3448" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="828df299-9a7a-4261-ac9c-fd7b18f423dd"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20221111"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0009-3448" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cleocin</name>
                        <formCode code="C28944" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CREAM"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>clindamycin phosphate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EH6D7113I8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CLINDAMYCIN PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3U02EL437C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CLINDAMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2DMT128M1S" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETOSTEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T5L8T28FGP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="CAL22UVI4M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 60</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="NVZ4I0H58X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SORBITAN MONOSTEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4ELV7Z65AP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="g" value="40"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43207" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE, WITH APPLICATOR"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-3448-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="19920811"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050680" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19920811"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38313" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VAGINAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_c51c756c-edec-4791-941e-5a5a0102b604">
               <id root="9406973c-a021-486a-a065-3063f8241e60"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>FOR INTRAVAGINAL USE ONLY<br/> NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</title>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="ID_65fefa39-3641-41f4-8300-e470122dad35">
               <id root="27721e56-5f19-404d-b043-412d81287789"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<content styleCode="italics">trans</content>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<content styleCode="italics">threo</content>-Î±â<content styleCode="italics">D-galacto</content>-octopyranoside 2-(dihydrogen phosphate). It has a molecular weight of 504.96, and the molecular formula is C<sub>18</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>8</sub>PS. The structural formula is represented below:</paragraph>
                  <renderMultiMedia ID="id284" referencedObject="MM1"/>
                  <paragraph>CLEOCIN Vaginal Cream 2%, is a semi-solid, white cream, which contains 2% clindamycin phosphate, USP, at a concentration equivalent to 20 mg clindamycin per gram. The pH of the cream is between 3.0 and 6.0. The cream also contains benzyl alcohol, cetostearyl alcohol, mixed fatty acid esters, mineral oil, polysorbate 60, propylene glycol, purified water, sorbitan monostearate, and stearic acid.</paragraph>
                  <paragraph>Each applicatorful of 5 grams of vaginal cream contains approximately 100 mg of clindamycin phosphate.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6a56af68-f66e-4f99-b2b9-599f097ee5d3">
               <id root="6cbd9f83-5f17-4783-b823-00d92b7a5ed6"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20221111"/>
               <component>
                  <section ID="ID_2bb0e326-d603-4f43-9a80-2bfb256d8311">
                     <id root="db3fe864-8c8f-4853-ae4e-ac1a4f2dc860"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Clindamycin is an antibacterial drug (See <linkHtml href="#MICRO">MICROBIOLOGY</linkHtml>).</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1dfa9d99-bc89-43e4-b2eb-71052d3b2865">
                     <id root="f80d46a3-7ad9-4e02-a1b3-6408afa0925f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered to 6 healthy female volunteers for 7 days, approximately 5% (range 0.6% to 11%) of the administered dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 18 ng/mL (range 4 to 47 ng/mL) and on day 7 it averaged 25 ng/mL (range 6 to 61 ng/mL). These peak concentrations were attained approximately 10 hours post-dosing (range 4â24 hours).</paragraph>
                        <paragraph>Following a once a day intravaginal dose of 100 mg of clindamycin phosphate vaginal cream 2%, administered for 7 consecutive days to 5 women with bacterial vaginosis, absorption was slower and less variable than that observed in healthy females. Approximately 5% (range 2% to 8%) of the dose was absorbed systemically. The peak serum clindamycin concentration observed on the first day averaged 13 ng/mL (range 6 to 34 ng/mL) and on day 7 it averaged 16 ng/mL (range 7 to 26 ng/mL). These peak concentrations were attained approximately 14 hours post-dosing (range 4â24 hours).</paragraph>
                        <paragraph>There was little or no systemic accumulation of clindamycin after repeated vaginal dosing of clindamycin phosphate vaginal cream 2%. The systemic half-life was 1.5 to 2.6 hours.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="MICRO">
               <id root="8345e1ac-4c61-4cff-a6e8-aff73193d5b3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>MICROBIOLOGY</title>
               <effectiveTime value="20221111"/>
               <component>
                  <section ID="ID_d78b893d-7599-4d25-b816-5a30035ea06b">
                     <id root="0975442b-6714-4127-a17d-a527f7a69016"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is predominantly bacteriostatic. Although clindamycin phosphate is inactive <content styleCode="italics">in vitro</content>, rapid <content styleCode="italics">in vivo</content> hydrolysis converts it to active clindamycin.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_58db228d-9736-440d-b203-f1672297a0ab">
                     <id root="dfcd3904-efa3-47af-9108-b06381fda7e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Resistance</title>
                     <text>
                        <paragraph>Resistance to clindamycin is most often caused by modification of the target site on the ribosome, usually by chemical modification of RNA bases by point mutations in RNA or occasionally in proteins. Cross resistance has been demonstrated between lincosamides, macrolides and streptogramins B in some organisms. Cross resistance has been demonstrated between clindamycin and lincomycin.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ac7e36f2-4298-4088-8476-0b19c95a232f">
                     <id root="9e5d5ef4-8091-4f85-a0d0-4864fca23653"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antibacterial Activity</title>
                     <text>
                        <paragraph>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis (see <linkHtml href="#Indications_and_Usage">INDICATIONS AND USAGE</linkHtml>); standard methodology for the susceptibility testing of the potential bacterial pathogens, <content styleCode="italics">Gardnerella vaginalis</content>, <content styleCode="italics">Mobiluncus</content> spp., or <content styleCode="italics">Mycoplasma hominis</content>, has not been defined.</paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available but their clinical significance is unknown. Clindamycin is active <content styleCode="italics">in vitro</content> against most isolates of the following organisms reported to be associated with bacterial vaginosis:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Bacteroides</content> spp.</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Gardnerella vaginalis</content>
                           </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Mobiluncus</content> spp.</item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Mycoplasma hominis</content>
                           </item>
                           <item>
                              <caption>â¢</caption>
                              <content styleCode="italics">Peptostreptococcus</content> spp.</item>
                        </list>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Indications_and_Usage">
               <id root="d0535d53-78cb-4354-b99a-4aabe1c5fb63"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as <content styleCode="italics">Haemophilus</content> vaginitis, <content styleCode="italics">Gardnerella</content> vaginitis, nonspecific vaginitis, <content styleCode="italics">Corynebacterium</content> vaginitis, or anaerobic vaginosis). CLEOCIN Vaginal Cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See <linkHtml href="#Clinical_Studies">CLINICAL STUDIES</linkHtml>.)</paragraph>
                  <paragraph>
                     <content styleCode="bold">NOTE</content>: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent <content styleCode="italics">Lactobacillus</content> morphology, (b) predominance of <content styleCode="italics">Gardnerella</content> morphotype, and (c) absent or few white blood cells.</paragraph>
                  <paragraph>Other pathogens commonly associated with vulvovaginitis, eg, <content styleCode="italics">Trichomonas vaginalis, Chlamydia trachomatis, N. gonorrhoeae, Candida albicans</content>, and <content styleCode="italics">Herpes simplex </content>virus should be ruled out.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="ID_a5d7b908-408a-49e2-a76b-1d64820d7f3a">
               <id root="80358722-3c76-4bea-8380-e3fe2eb6df6f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Cream 2%, is contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal cream. CLEOCIN Vaginal Cream 2%, is also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Warnings">
               <id root="8429c5e4-1242-4ce7-81fd-10ca77159e58"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal and vaginal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of clindamycin, even when administered by the vaginal route, because approximately 5% of the clindamycin dose is systemically absorbed from the vagina.</content>
                  </paragraph>
                  <paragraph>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia.Studies indicate that a toxin produced by <content styleCode="italics">Clostridioides difficile</content> is a primary cause of "antibiotic-associated" colitis.</paragraph>
                  <paragraph>After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <content styleCode="italics">Clostridioides difficile</content> colitis.</paragraph>
                  <paragraph>Onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Precautions">
               <id root="ec7412c7-220e-46c6-8291-795a38419521"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20250403"/>
               <component>
                  <section ID="General">
                     <id root="316a6595-f5a1-450b-b804-700f94b040cc"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>CLEOCIN Vaginal Cream 2%, contains ingredients that will cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water.</paragraph>
                        <paragraph>The use of CLEOCIN Vaginal Cream 2% may result in the overgrowth of nonsusceptible organisms in the vagina. In clinical studies involving 600 non-pregnant women who received treatment for 3 days, <content styleCode="italics">Candida albicans</content> was detected, either symptomatically or by culture, in 8.8% of patients. In 9% of the patients, vaginitis was recorded. In clinical studies involving 1325 non-pregnant women who received treatment for 7 days, <content styleCode="italics">Candida albicans</content> was detected, either symptomatically or by culture, in 10.5% of patients. Vaginitis was recorded in 10.7% of the patients. In 180 pregnant women who received treatment for 7 days, <content styleCode="italics">Candida albicans</content> was detected, either symptomatically or by culture, in 13.3% of patients. In 7.2% of the patients, vaginitis was recorded. <content styleCode="italics">Candida albicans</content>, as reported here, includes the terms: vaginal moniliasis and moniliasis (body as a whole). Vaginitis includes the terms: vulvovaginal disorder, vulvovaginitis, vaginal discharge, trichomonal vaginitis, and vaginitis.</paragraph>
                     </text>
                     <effectiveTime value="20250403"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_ac5e846c-e9d2-4591-8655-c1f51dfb2f45">
                     <id root="51508cfb-7ae9-489f-94c3-76c7aa4afd5a"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>The patient should be instructed not to engage in vaginal intercourse, or use other vaginal products (such as tampons or douches) during treatment with this product.</paragraph>
                        <paragraph>
                           <content styleCode="bold">The patient should also be advised that this cream contains mineral oil that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, use of such products within 72 hours following treatment with CLEOCIN Vaginal Cream 2%, is not recommended.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5790cf40-d883-434b-8466-9e3f157bafdf">
                     <id root="7ed63332-b182-4a56-8aa1-ecf3793ff2a1"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Systemic clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a921699a-1548-4d20-a87e-53e28ebd9269">
                     <id root="d67a82b4-518f-4c1f-9f12-1d1239bc2588"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential.</paragraph>
                        <paragraph>Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m<sup>2</sup>) revealed no effects on fertility or mating ability.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_074efccc-5890-4e97-9b77-3c7fc1977f4d">
                     <id root="fb0b199d-631b-4513-97d2-e30b32a68dc5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20221111"/>
                     <component>
                        <section ID="ID_7148d5ed-f09b-4cfa-b653-7d71350ebef7">
                           <id root="d0d97592-29d0-49cc-bd71-91fb629b1133"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic effects</content>
                           </title>
                           <text>
                              <paragraph>In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.</paragraph>
                              <paragraph>Clindamycin vaginal cream should be used during the first trimester of pregnancy only if clearly needed and the benefits outweigh the risks. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.</paragraph>
                              <paragraph>CLEOCIN Vaginal Cream 2% has been studied in pregnant women during the second trimester. In women treated for seven days, abnormal labor was reported in 1.1% of patients who received clindamycin vaginal cream 2% compared with 0.5% of patients who received placebo.</paragraph>
                              <paragraph>Reproduction studies have been performed in rats and mice using oral and parenteral doses of clindamycin up to 600 mg/kg/day (62 and 25 times, respectively, the maximum human exposure based on body surface area) and have revealed no evidence of harm to the fetus due to clindamycin. Cleft palates were observed in fetuses from one mouse strain treated intraperitoneally with clindamycin at 200 mg/kg/day (about 10 times the recommended dose based on body surface area conversions). Since this effect was not observed in other mouse strains or in other species, the effect may be strain specific.</paragraph>
                           </text>
                           <effectiveTime value="20221111"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_c9816065-fb81-41e1-8a98-92eb5be9c834">
                     <id root="ae898ac1-eda3-4448-822f-2e70e4fb9931"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. It is not known if clindamycin is excreted in human breast milk following the use of vaginally administered clindamycin phosphate.</paragraph>
                        <paragraph>Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. If clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3af75e3a-ebe2-4c81-a72f-e01cf3918d81">
                     <id root="200a11d0-698a-4b27-872f-d86a30459da8"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_26d4d5f6-d98c-4b93-956a-7e4f1bccd04d">
                     <id root="88d21bf9-0ff4-4071-b182-41ac6d467907"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies for CLEOCIN Vaginal Cream 2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20221111"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Adverse_Reactions">
               <id root="28427c86-cb96-45ee-ad79-0b0243f7bfee"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20250403"/>
               <component>
                  <section ID="ID_dfdd3a91-f226-4e7a-a362-5ac153a57cd9">
                     <id root="1a93e19c-1c87-4e7f-b514-9ee5127430ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Clinical trials</title>
                     <effectiveTime value="20250403"/>
                     <component>
                        <section ID="ID_f8a5d4f1-4933-4543-949e-e40c2d5b3301">
                           <id root="afa89ed7-e0fb-4dd4-9800-14e9de3edc17"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Non-pregnant Women</content>
                           </title>
                           <text>
                              <paragraph>In clinical trials involving non-pregnant women, 1.8% of 600 patients who received treatment with CLEOCIN Vaginal Cream 2% for 3 days and 2.7% of 1325 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 20.7% of the patients receiving treatment for 3 days and 21.3% of the patients receiving treatment for 7 days. Events occurring in â¥1% of patients receiving clindamycin phosphate vaginal cream 2% are shown in Table 1.</paragraph>
                              <table ID="_RefID0EABAE" width="75%">
                                 <caption>TABLE 1 â Events Occurring in â¥1% of Non-pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2%</caption>
                                 <col width="29%"/>
                                 <col width="25%"/>
                                 <col width="20%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Botrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">Event</content>
                                       </th>
                                       <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">CLEOCIN Vaginal Cream</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Lrule Botrule " valign="middle">
                                          <content styleCode="bold">3 Day</content>
                                          <br/>
                                          <content styleCode="bold">n=600</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <content styleCode="bold">7 Day</content>
                                          <br/>
                                          <content styleCode="bold">n=1325</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Toprule " valign="middle">
                                          <paragraph>
                                             <content styleCode="underline">Urogenital</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Lrule Toprule " valign="middle"/>
                                       <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>Â Â Vaginal moniliasis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule " valign="middle">
                                          <paragraph>7.7</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule " valign="middle">
                                          <paragraph>10.4</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>Â Â Vulvovaginitis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule " valign="middle">
                                          <paragraph>6.0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule " valign="middle">
                                          <paragraph>4.4</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>Â Â Vulvovaginal disorder</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule " valign="middle">
                                          <paragraph>3.2</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule " valign="middle">
                                          <paragraph>5.3</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>Â Â Trichomonal vaginitis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>0</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>1.3</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="underline">Body as a Whole</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Lrule " valign="middle"/>
                                       <td styleCode="Rrule Lrule " valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule Lrule " valign="middle">
                                          <paragraph>Â Â Moniliasis (body)</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Lrule " valign="middle">
                                          <paragraph>1.3</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                          <paragraph>0.2</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Other events occurring in &lt;1% of the clindamycin vaginal cream 2% groups include:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Urogenital system</content>: vaginal discharge, metrorrhagia, urinary tract infection, endometriosis, menstrual disorder, vaginitis/vaginal infection, and vaginal pain.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Body as a whole</content>: localized abdominal pain, generalized abdominal pain, abdominal cramps, halitosis, headache, bacterial infection, inflammatory swelling, allergic reaction, and fungal infection.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Digestive system</content>: nausea, vomiting, constipation, dyspepsia, flatulence, diarrhea, and gastrointestinal disorder.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Endocrine system</content>: hyperthyroidism.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Central nervous system</content>: dizziness and vertigo.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Respiratory system</content>: epistaxis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin</content>: pruritus (non-application site), moniliasis, rash, maculopapular rash, erythema, and urticaria.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Special senses</content>: taste perversion.</paragraph>
                           </text>
                           <effectiveTime value="20250403"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_114de09b-db9e-4e98-b296-bd08277a2204">
                           <id root="76144967-e4fa-4aa4-adf0-9c92dd6a97ed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Pregnant Women</content>
                           </title>
                           <text>
                              <paragraph>In a clinical trial involving pregnant women during the second trimester, 1.7% of 180 patients who received treatment for 7 days discontinued therapy due to drug-related adverse events. Medical events judged to be related, probably related, possibly related, or of unknown relationship to vaginally administered clindamycin phosphate vaginal cream 2%, were reported for 22.8% of pregnant patients. Events occurring in â¥1% of patients receiving either clindamycin phosphate vaginal cream 2% or placebo are shown in Table 2.</paragraph>
                              <table ID="_RefID0EJFAE" width="75%">
                                 <caption>TABLE 2 - Events Occurring in â¥1% of Pregnant Patients Receiving Clindamycin Phosphate Vaginal Cream 2% or Placebo</caption>
                                 <col width="28%"/>
                                 <col width="26%"/>
                                 <col width="20%"/>
                                 <thead>
                                    <tr>
                                       <th align="left" rowspan="2" styleCode="Botrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">Event</content>
                                       </th>
                                       <th align="center" styleCode="Botrule Lrule Toprule " valign="middle">
                                          <content styleCode="bold">CLEOCIN </content>
                                          <br/>
                                          <content styleCode="bold">Vaginal Cream</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                          <content styleCode="bold">Placebo</content>
                                       </th>
                                    </tr>
                                    <tr>
                                       <th align="center" styleCode="Lrule Botrule " valign="middle">
                                          <content styleCode="bold">7 DAY</content>
                                          <br/>
                                          <content styleCode="bold">n=180</content>
                                       </th>
                                       <th align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <content styleCode="bold">7 DAY</content>
                                          <br/>
                                          <content styleCode="bold">n=184</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Toprule " valign="middle">
                                          <paragraph>
                                             <content styleCode="underline">Urogenital</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Lrule Toprule " valign="middle"/>
                                       <td styleCode="Rrule Lrule Toprule " valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>Â Â Vaginal moniliasis</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule " valign="middle">
                                          <paragraph>13.3</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule " valign="middle">
                                          <paragraph>7.1</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>Â Â Vulvovaginal disorder</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule " valign="middle">
                                          <paragraph>6.7</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule " valign="middle">
                                          <paragraph>7.1</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>Â Â Abnormal labor</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>1.1</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>0.5</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="underline">Body as a Whole</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Lrule " valign="middle"/>
                                       <td styleCode="Rrule Lrule " valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>Â Â Fungal infection</paragraph>
                                       </td>
                                       <td align="center" styleCode="Lrule Botrule " valign="middle">
                                          <paragraph>1.7</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                          <paragraph>0</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule " valign="middle">
                                          <paragraph>
                                             <content styleCode="underline">Skin</content>
                                          </paragraph>
                                       </td>
                                       <td styleCode="Lrule " valign="middle"/>
                                       <td styleCode="Rrule Lrule " valign="middle"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Botrule Lrule " valign="middle">
                                          <paragraph>Â Â Pruritus, non-application site</paragraph>
                                       </td>
                                       <td align="center" styleCode="Botrule Lrule " valign="middle">
                                          <paragraph>1.1</paragraph>
                                       </td>
                                       <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                          <paragraph>0</paragraph>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Other events occurring in &lt;1% of the clindamycin vaginal cream 2% group include:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Urogenital system</content>: dysuria, metrorrhagia, vaginal pain, and trichomonal vaginitis.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Body as a whole</content>: upper respiratory infection.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Skin</content>: pruritus (topical application site) and erythema.</paragraph>
                           </text>
                           <effectiveTime value="20250403"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_e6d39f13-e1d4-4e3b-9142-53c2b9ae2673">
                           <id root="c0b10341-1a0c-441b-a470-7177fe3baec6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Post-marketing Experience</content>
                           </title>
                           <text>
                              <paragraph>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                              <paragraph>In the post-marketing period, there have been case reports of pseudomembranous colitis with the use of clindamycin phosphate vaginal cream. </paragraph>
                           </text>
                           <effectiveTime value="20221111"/>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2d64bd48-218b-4bdd-a170-f85ab1fdd3e8">
                           <id root="6e9b3b21-0eda-4d4a-b554-be1653dfc3ed"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">Other clindamycin formulations</content>
                           </title>
                           <text>
                              <paragraph>Clindamycin vaginal cream affords minimal peak serum levels and systemic exposure (AUCs) of clindamycin compared to 100 mg oral clindamycin dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral clindamycin, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing clindamycin administered orally to clindamycin administered vaginally are not available.</paragraph>
                              <paragraph>The following adverse reactions and altered laboratory tests have been reported with the <content styleCode="bold">oral or parenteral</content> use of clindamycin:</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Infections and Infestations: Clostridioides difficile</content> colitis</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Gastrointestinal</content>: Abdominal pain, esophagitis, nausea, vomiting, diarrhea, and pseudomembranous colitis. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hematopoietic</content>: Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hypersensitivity Reactions</content>: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Liver</content>: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Musculoskeletal</content>: Cases of polyarthritis have been reported.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Renal</content>: Acute kidney injury</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Immune System:</content> Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported. </paragraph>
                           </text>
                           <effectiveTime value="20221111"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_65ea6450-8cda-48b0-95c5-28d509f48b14">
               <id root="c8b7b8a3-e8d6-46f4-892f-da76fe770823"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Vaginally applied clindamycin phosphate vaginal cream 2% could be absorbed in sufficient amounts to produce systemic effects. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="ID_2dfbded6-6d39-43bc-b363-a5d067710bc6">
               <id root="33ea2593-6704-4e5d-8f0d-e4e95e4f7bdb"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dose is one applicatorful of clindamycin phosphate vaginal cream 2%, (5 grams containing approximately 100 mg of clindamycin phosphate) intravaginally, preferably at bedtime, for 3 or 7 consecutive days in non-pregnant patients and for 7 consecutive days in pregnant patients. (See <linkHtml href="#Clinical_Studies">CLINICAL STUDIES</linkHtml>.)</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="ID_481184fc-d2c9-45b6-9545-d163a440274b">
               <id root="4c6c7b75-6d9f-4f14-b977-44b86e3ad01a"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Cream 2%, (clindamycin phosphate vaginal cream) is supplied as follows:</paragraph>
                  <paragraph>40 g tube (with 7 disposable applicators)Â Â Â Â Â Â Â Â  NDC 0009-3448-01</paragraph>
                  <paragraph>Store at controlled room temperature 20Â° to 25Â° C (68Â° to 77Â° F) [see USP]. Protect from freezing.</paragraph>
               </text>
               <effectiveTime value="20221111"/>
            </section>
         </component>
         <component>
            <section ID="Clinical_Studies">
               <id root="ac6c06b7-4c9b-412e-867f-2832242444f0"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>CLINICAL STUDIES</title>
               <text>
                  <paragraph>In two clinical studies involving 674 evaluable non-pregnant women with bacterial vaginosis comparing CLEOCIN Vaginal Cream 2% for 3 or 7 days, the clinical cure rates, determined at 1 month posttherapy, ranged from 72% to 81% for the 3-day treatment and 84% to 86% for the 7-day treatment.</paragraph>
                  <table width="50%">
                     <col width="14%"/>
                     <col width="10%"/>
                     <col width="7%"/>
                     <col width="10%"/>
                     <col width="7%"/>
                     <thead>
                        <tr>
                           <th align="left" styleCode="Botrule Toprule " valign="middle"/>
                           <th align="center" colspan="2" styleCode="Botrule Toprule " valign="middle">
                              <content styleCode="bold">CLEOCIN 3 Day</content>
                           </th>
                           <th align="center" colspan="2" styleCode="Botrule Toprule " valign="middle">
                              <content styleCode="bold">CLEOCIN 7 Day</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule " valign="middle">
                              <paragraph>US Study</paragraph>
                           </td>
                           <td align="center" styleCode="Toprule " valign="middle">
                              <paragraph>94/131</paragraph>
                           </td>
                           <td align="center" styleCode="Toprule " valign="middle">
                              <paragraph>72%</paragraph>
                           </td>
                           <td align="center" styleCode="Toprule " valign="middle">
                              <paragraph>110/128</paragraph>
                           </td>
                           <td align="center" styleCode="Toprule " valign="middle">
                              <paragraph>86%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule " valign="middle">
                              <paragraph>European Study</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="middle">
                              <paragraph>161/199</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="middle">
                              <paragraph>81%</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="middle">
                              <paragraph>181/216</paragraph>
                           </td>
                           <td align="center" styleCode="Botrule " valign="middle">
                              <paragraph>84%</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>In a clinical study involving 249 evaluable pregnant patients in the second and third trimester treated for 7 days, the clinical cure rate, determined at 1 month posttherapy, was 60% (77/129) in the clindamycin arm and 9% (11/120) for the vehicle arm. The determination of clinical cure was based on the absence of a "fishy" amine odor when the vaginal discharge was mixed with a 10% KOH solution and the absence of clue cells on microscopic examination.</paragraph>
               </text>
               <effectiveTime value="20250403"/>
            </section>
         </component>
         <component>
            <section ID="ID_7670494b-0e64-461d-8c7c-7f8d122a5cf2">
               <id root="36f4cfbd-f6aa-4a84-9332-2514d95f8f8d"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.</paragraph>
                  <renderMultiMedia ID="id780" referencedObject="MM2"/>
                  <paragraph>LAB-0043-15.0<br/>Revised 3/2025</paragraph>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>A close-up of a logo  AI-generated content may be incorrect.</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_d5c32cda-4802-4edc-9d93-7271c174ba02">
               <id root="aecda3b9-e04e-4610-868b-b780d902b946"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>DIRECTIONS FOR USE</title>
               <text>
                  <paragraph>Disposable plastic applicators are provided with this package. They are designed to allow proper vaginal administration of the cream.</paragraph>
                  <paragraph>Remove cap from cream tube. Screw a plastic applicator on the threaded end of the tube.</paragraph>
                  <paragraph>Rolling tube from the bottom, squeeze gently and force the medication into the applicator. The applicator is filled when the plunger reaches its predetermined stopping point.</paragraph>
                  <paragraph>Unscrew the applicator from the tube and replace the cap.</paragraph>
                  <renderMultiMedia ID="id801" referencedObject="MM3"/>
                  <paragraph>While lying on your back, firmly grasp the applicator barrel and insert into vagina as far as possible without causing discomfort.</paragraph>
                  <paragraph>Slowly push the plunger until it stops.</paragraph>
                  <paragraph>Carefully withdraw applicator from vagina, and discard applicator.</paragraph>
                  <renderMultiMedia ID="id805" referencedObject="MM4"/>
                  <paragraph>REMEMBER TO APPLY ONE APPLICATORFUL EACH NIGHT BEFORE BEDTIME, OR AS PRESCRIBED BY YOUR DOCTOR.</paragraph>
                  <paragraph>
                     <content styleCode="bold">INSTRUCCIONES PARA LA PACIENTE</content>
                  </paragraph>
                  <paragraph>Este envase contiene aplicadores de plÃ¡stico desechables. Los aplicadores estÃ¡n diseÃ±ados para la administraciÃ³n apropiada de la crema en la vagina.</paragraph>
                  <paragraph>Remueva la tapa del tubo de crema y enrosque el aplicador de plÃ¡stico al tubo.</paragraph>
                  <paragraph>Exprima el tubo suavemente desde el extremo inferior y fuerce el medicamento al aplicador. El aplicador estarÃ¡ lleno cuando el Ã©mbolo llega a su mÃ¡xima longitud. </paragraph>
                  <paragraph>Desenrosque el aplicador del tubo y vuelva a poner la tapa.</paragraph>
                  <renderMultiMedia ID="id813" referencedObject="MM5"/>
                  <paragraph>AcuÃ©stese de espalda y agarrando firmemente el aplicador, introdÃºzcalo en la vagina tanto como sea posible sin causar molestias.</paragraph>
                  <paragraph>Empuje lentamente el Ã©mbolo hasta que se detenga.</paragraph>
                  <paragraph>Saque el aplicador cuidadosamente de la vagina y descÃ¡rtelo.</paragraph>
                  <renderMultiMedia ID="id817" referencedObject="MM6"/>
                  <paragraph>RECUERDE APLICARSE UN APLICADOR LLENO TODAS LAS NOCHES AL ACOSTARSE, O DE ACUERDO CON LAS INDICACIONES DE SU MEDICO.</paragraph>
                  <paragraph>LAB-1058-1.0</paragraph>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_1fc92960-a83d-44ed-84f3-705f718b0b52">
               <id root="99661624-fa71-45e7-bf72-b5652a663dfc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 40 g Tube Label</title>
               <text>
                  <paragraph>NDC 0009-3448-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">40 Gram</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cleocin</content>
                     <sup>Â®</sup>
                     <br/>clindamycin phosphate<br/>vaginal cream, USP</paragraph>
                  <paragraph>For Intravaginal Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">2%*</content>
                  </paragraph>
                  <renderMultiMedia ID="id860" referencedObject="MM7"/>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>PRINCIPAL DISPLAY PANEL - 40 g Tube Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f81392f9-f127-4e8c-bca0-a82e5cc13b3e">
               <id root="aac3e67e-9e0f-4c55-adf6-e62bec86f65a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 40 g Tube Carton</title>
               <text>
                  <paragraph>NDC 0009-3448-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">40 Gram With 7 Applicators</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Cleocin</content>
                     <sup>Â®</sup>
                     <br/>clindamycin phosphate<br/>vaginal cream, USP</paragraph>
                  <paragraph>For Intravaginal Use Only</paragraph>
                  <paragraph>
                     <content styleCode="bold">2%*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Pfizer</content>
                     </content>
                     <br/>
                     <content styleCode="italics">Distributed by</content>
                     <br/>
                     <content styleCode="bold">Pharmacia &amp; Upjohn Co</content>
                     <br/>Division of Pfizer Inc, NY, NY 10017</paragraph>
                  <renderMultiMedia ID="id893" referencedObject="MM8"/>
               </text>
               <effectiveTime value="20221111"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>PRINCIPAL DISPLAY PANEL - 40 g Tube Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>